Compounded Transdermal Medications in Veterinary Patients: Separating Convenience from Clinical Reality

Transdermal medications are easy to like, and for good reason. They are often less stressful for both the patient and the caregiver, particularly in cats that are difficult to medicate orally. In many practices, they have come to represent a more compassionate approach to care. In certain situations, they are absolutely the right choice.

The challenge is that convenience and clinical reliability are not the same thing.

Changing a drug to a transdermal route is not a simple substitution. It alters how the drug enters the body, how much is absorbed, and how predictable the response will be. In human medicine, transdermal products are developed through extensive formulation work, permeability studies, and pharmacokinetic validation. In veterinary medicine, most transdermal use relies on extrapolation, which introduces a level of uncertainty that is not always fully appreciated.

The skin itself is a significant barrier. Drug absorption depends on factors such as molecular size, lipophilicity, concentration gradient, the composition of the base, and the site of application. In veterinary patients, additional variability is introduced by grooming behavior, hair density, and species-specific differences in skin structure. As a result, two patients receiving the same preparation may experience very different levels of drug exposure.

This variability becomes particularly important when transdermal formulations are used for drugs that do not reliably achieve systemic absorption through the skin. Gabapentin is a common example. Although it is widely used in transdermal form, pharmacokinetic data have consistently shown that plasma concentrations in many cats are low or undetectable. When a patient appears to improve, it can be difficult to determine whether that improvement is due to the medication, natural fluctuation in the condition, or other concurrent therapies. In these cases, the drug may not be contributing in a meaningful way, even though it appears that it should.

Dose requirements introduce another limitation. Transdermal delivery can only accommodate a certain amount of drug crossing the skin over time. Medications that require higher doses or consistent systemic exposure are often poor candidates for this route. Increasing the concentration of the preparation does not reliably overcome this barrier and may instead increase local irritation without improving absorption.

The choice of vehicle further complicates the picture. Transdermal bases are not interchangeable, and their performance varies depending on the drug being used. Stability, drug release, and absorption can differ significantly between preparations that appear identical on the label. Without drug-specific validation, it is difficult to assume that two formulations will behave the same way in practice.

There are also safety considerations that are easy to overlook. Transdermal medications can be transferred through skin contact to caregivers or other animals in the household. In multi-pet environments, this becomes a real concern. Certain drugs, including hormones and chemotherapy agents, carry additional risks, particularly for individuals who are pregnant or of reproductive age. These factors require clear counseling and careful handling, even when the medication itself appears straightforward.

None of this suggests that transdermal compounding should be avoided. There are situations in which it is appropriate and supported by both pharmacokinetic data and clinical experience. Methimazole is a well-established example in cats, where transdermal use can be both practical and effective.

Transdermal application of medication on a feline.

A useful starting point is to consider what the drug needs to accomplish. If the goal is rapid or reliable systemic exposure, transdermal delivery may not be the best option. If the drug has a narrow therapeutic window, variability in absorption introduces additional risk. If treatment success depends on subtle clinical changes, inconsistent exposure can make interpretation more difficult.

Convenience remains an important consideration, particularly when administration challenges affect adherence. However, it cannot be the only factor guiding the decision. When transdermal therapy is selected primarily to make administration easier, it should be accompanied by a clear plan to reassess whether the medication is achieving the intended effect. Without that reassessment, it becomes easy to assume that treatment is working when it may not be.

Ultimately, veterinary patients benefit from therapies that are chosen based on how they perform, not simply how easy they are to give.